Arch Oncology, Inc. is a privately-held, clinical-stage immuno-oncology company focused on the discovery and development of novel antibody-based therapeutics for the treatment of patients with cancer. Their lead product candidate, AO-176, is a highly differentiated anti-CD47 antibody designed to have a best-in-class profile by directly killing tumor cells, blocking the 'don't eat me' signal (CD47-SIRPα interaction), and sparing red blood cells. The company is advancing AO-176 in multiple clinical trials for both solid tumors and hematologic malignancies.
The headquarters serves as the central hub for Arch Oncology's research and development, clinical operations, strategic planning, and corporate administration.
Located in a key biotechnology cluster in the San Francisco Bay Area, providing access to a rich talent pool and collaborative opportunities. The facility likely includes modern laboratory and office spaces conducive to biopharmaceutical research.
A dynamic, science-driven, and collaborative environment typical of clinical-stage biotech companies. Emphasis is likely placed on innovation, rigorous scientific methodology, and a shared mission to improve patient outcomes in oncology.
The Brisbane headquarters is pivotal for driving the company's scientific innovation, managing its clinical trial programs for AO-176, and engaging with the broader biotech ecosystem.
While Arch Oncology's primary operations and headquarters are in the United States, its clinical development programs for AO-176 involve trial sites that may be located internationally to ensure diverse patient populations and accelerate recruitment. The company's partnerships and collaborations can also extend its reach globally, aiming to bring its innovative cancer therapies to patients worldwide upon successful development and approval.
7000 Marina Boulevard, Suite M200
Brisbane
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Arch Oncology' leadership includes:
Arch Oncology has been backed by several prominent investors over the years, including:
Based on publicly available information, there have been no major widely reported executive hires or departures at Arch Oncology in the last 12 months. The leadership team appears to be stable.
Discover the tools Arch Oncology uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Common email formats at Arch Oncology likely follow standard corporate patterns using the archoncology.com domain. The most probable formats include first initial followed by last name, or first name and last name separated by a dot.
[first_initial][last]@archoncology.com (e.g., jdoe@archoncology.com) or [first].[last]@archoncology.com (e.g., jane.doe@archoncology.com)
Format
pfalardeau@archoncology.com
Example
80%
Success rate
Arch Oncology Website • October 26, 2022
Arch Oncology, Inc. announced that new clinical data on AO-176, its anti-CD47 antibody, will be presented at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, taking place November 8-12, 2022, in Boston, MA. The presentation will include updated safety and efficacy data from ongoing Phase 1/2 clinical trials in multiple myeloma and solid tumors....more
PR Newswire • April 7, 2021
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of anti-CD47 antibody therapies, today announced the closing of a $105 million Series C financing. The financing was co-led by new investors, Eventide Asset Management and Cowen Healthcare Investments, along with existing investors....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Arch Oncology, are just a search away.